Aug 10 (Reuters) - Arch Biopartners Inc ACH.V :
* Engaged Catalent Inhalation, a division of Catalent Pharma Solutions, to begin manufacturing process for drug ab569
* Catalent Inhalation to undertake initial stability and formulation studies, later manufacture a supply of ab569
* Engaged Catalent Inhalation in preparation for first human trials involving patients with antibiotic resistant lung infections Source text for Eikon: ID:nMKWMfdXpa Further company coverage: ACH.V